Skip To Main Content
Michael O'Riordan on Muck Rack

Michael O'Riordan

Verified
  • Senior Journalist, Cardiovascular Research Foundation, TCTMD
Hamilton
As seen in: TCTMD, Medscape, NewsBreak, The Tablet, FundsPeople, Our Community Now, ETF Stream
Medical journalist with @TCTMD. Likes running marathons, baseball, and vegetarian food. Dislikes snow, flat (bike) tires, and stress fractures.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evolocumab Cuts MACE Risk in Stented Patients Without Prior MI VESALIUS-CV

|
By Michael O'Riordan Verified
| TCTMD Verified
News Conference News EuroPCR 2026 In this high-risk population, those who had a prior PCI had higher event rates but benefited from aggressive LDL-lowering. PARIS, France—Patients with atherosclerosis or high-risk diabetes who have undergone PCI, but who have not yet had an MI or stroke, fare significantly better when LDL-cholesterol levels are treated aggressively with a PCSK9 inhibitor, according to a new VESALIUS-CV analysis presented today at EuroPCR 2026.
Open in Who Shared Issue with article?

PREVENT and SCORE2 Prediction Tools Perform Well in Global Cohort

|
By Michael O'Riordan Verified
| TCTMD Verified
With another 2 million diverse patients, including some from RCTs, the calculators were effective at identifying those at risk. The PREVENT and SCORE2 cardiovascular risk calculators both perform well across diverse clinical and population groups, according to results of a large global study. Discrimination was stronger in the low- and intermediate-risk populations, a finding that strengthens the tools’ use in the primary-care setting, say researchers.
Open in Who Shared Issue with article?

What’s Going to Be Hot at EuroPCR 2026?

|
By Michael O'Riordan Verified
| TCTMD Verified
News Conference News EuroPCR 2026 It’s going to be a busy 4 days in Paris, with 166 late-breaking studies and nearly 2,000 clinical cases to be presented. In just over a week, EuroPCR 2026, one of the leading courses in interventional medicine, is set to kick off in Paris, France, a city in full bloom at this time of year.
Open in Who Shared Issue with article?
See all 2,474 licensed articles (2,475 Total)